Preclinical trials in the SIV/macaques model demonstrate the induction of SIV-specific polyfunctional CD4+ and CD8+ T cell activity resulting in marked decreases in viral load using DNA or viral vector vaccine strategy as either post-infection therapy or prophylaxis against SIV (117–120). The gene discussed is CD4; the disease is infection.